Both Seres Therapeutics Inc. (NASDAQ:MCRB) and Actinium Pharmaceuticals Inc. (NYSEAMERICAN:ATNM) are each other’s competitor in the Biotechnology industry. Thus the compare of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics Inc.	28.27M	10.12	98.94M	-2.62	0.00
Actinium Pharmaceuticals Inc.	N/A	0.00	23.65M	-0.22	0.00

Table 1 shows the top-line revenue, earnings per share and valuation for Seres Therapeutics Inc. and Actinium Pharmaceuticals Inc.

Profitability

Table 2 shows us the return on assets, net margins and return on equity of both businesses.

	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics Inc.	-349.98%	0%	-72.2%
Actinium Pharmaceuticals Inc.	0.00%	-139.9%	-106.2%

Risk and Volatility

Seres Therapeutics Inc. has a 1.79 beta, while its volatility is 79.00% which is more volatile than Standard and Poor’s 500. Competitively, Actinium Pharmaceuticals Inc.’s 159.00% volatility makes it more volatile than Standard and Poor’s 500, because of the 2.59 beta.

Liquidity

Seres Therapeutics Inc. has a Current Ratio of 2 and a Quick Ratio of 2. Competitively, Actinium Pharmaceuticals Inc.’s Current Ratio is 3.7 and has 3.7 Quick Ratio. Actinium Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Seres Therapeutics Inc.

Analyst Ratings

Seres Therapeutics Inc. and Actinium Pharmaceuticals Inc. Recommendations and Ratings are available on the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Seres Therapeutics Inc.	0	0	4	3.00
Actinium Pharmaceuticals Inc.	0	0	0	0.00

Seres Therapeutics Inc.’s upside potential is 100.86% at a $14 consensus target price.

Institutional and Insider Ownership

The shares of both Seres Therapeutics Inc. and Actinium Pharmaceuticals Inc. are owned by institutional investors at 78% and 12.8% respectively. 1.2% are Seres Therapeutics Inc.’s share owned by insiders. Competitively, 0.2% are Actinium Pharmaceuticals Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Seres Therapeutics Inc.	5.72%	1.95%	-25.06%	-27.06%	-34.17%	38.94%
Actinium Pharmaceuticals Inc.	-0.02%	11.69%	26.51%	-3.89%	44.16%	60.18%

For the past year Seres Therapeutics Inc. has weaker performance than Actinium Pharmaceuticals Inc.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. Its product candidates in pre-clinical development comprise SER-301, a synthetic Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-155, an Ecobiotic microbiome therapeutic for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The companyÂ’s proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its lead product candidate is Iomab-B that is in Phase III clinical studies in refractory or relapsed acute myeloid leukemia (AML) patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60; and Actimab-M that is in Phase I clinical trials for patients with relapsed or refractory multiple myeloma. In addition, it utilizes its alpha-particle immunotherapy technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.